Top stories in hematology/oncology: COVID-19 may cause long-term changes to cancer care, ASCO announces award recipients
In a recent interview, David E. Cohn, MD, MBA, discussed ways the COVID-19 pandemic is likely to change the practice of oncology. It was the top story in hematology/oncology last week.
Another top story was about the recipients of the American Society of Clinical Oncology (ASCO) awards, who were recognized for their outstanding contributions to cancer care.
Read these and more of the week’s top stories in hematology/oncology below:
COVID-19 response may lead to lasting changes in cancer care
Throughout history, crisis situations often have forced provisional changes that, upon further reflection, have been deemed worthy of permanent institution. Read more.
ASCO awards recognize outstanding contributions to cancer care
ASCO announced the recipients of several awards intended to honor researchers and other leaders in oncology who strive to transform cancer care. Read more.
Racial disparities observed in guideline-recommended lung cancer imaging
Blacks and Hispanics appeared less likely than non-Hispanic whites to receive guideline-recommended PET/CT imaging at the time of lung cancer diagnosis, according to results of a study published in Journal of the National Cancer Institute. Read more.
Off-the-shelf CAR T-cell therapy effective for advanced T-cell acute lymphoblastic leukemia
TruUCAR GC027 — a gene edited, investigational allogeneic chimeric antigen receptor T-cell therapy — showed efficacy for treatment of relapsed or refractory T-cell acute lymphoblastic leukemia, according to preliminary results of a first-in-human study presented at the virtual American Association for Cancer Research Annual Meeting. Read more.
CAR-T plus atezolizumab safe, effective in refractory diffuse large B-cell lymphoma
Treatment with the anti-PD-L1 antibody atezolizumab after the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel appeared safe and clinically effective for refractory diffuse large B cell lymphoma, according to phase 2 results of the ZUMA-6 trial presented at the virtual American Association for Cancer Research Annual Meeting. Read more.